FIGURE 1
FROM:
Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma
J J Ord, E Streeter, A Jones, K Le Monnier, D Cranston, J Crew, S P Joel, M A Rogers, R E Banks, I S D Roberts and A L Harris
BACK TO ARTICLEFigure 1.
Mean postdose urinary Suramin concentrations by dose level (see Table 1). This represents the concentration of urine drained from the bladder at the end of the 2-h instillation. Error bar equals 1 s.d. Differences between groups are highly significant (two-tailed t-test, variances not assumed to be equal P<0.01).
